A PSMA aptamer-siRNA conjugate targeting prostate cancer was developed to suppress the expression of pro-survival genes such as polo-like kinase 1 (PLK1) and B cell lymphoma 2 (BCL2) (Figure 2A) [100]. This evidence concerns the gene FOLH1 and prostate carcinoma.